RegeneRx has designed each formulation to serve a number of target disease indications within a broad area of interest. Each indication is supported by patents and research data, much of which have been published in peer-reviewed scientific and medical journals. Although RegeneRx cannot pursue all of these indications, partners have an opportunity to optimize indications that are important to their own therapeutic area of focus.
|
PRODUCT CANDIDATE |
TARGET INDICATION |
APPROXIMATE U.S. POPULATION/YEAR* |
| RGN-259 (Tβ4 Eye Drop) |
Dry Eye Syndrome Neurotrophic Keratopathy (orphan) Recurrent Corneal Erosions Corneal Surgeries |
20M ~10K** 2.8M 1.3M |
| RGN-352 (Tβ4 Injectable Solution) |
Acute Myocardial Infarction (AMI) Peripheral Neuropathy Stroke Traumatic Brain Injury (TBI) Multiple Sclerosis |
650K 15M 700K 500K 300K |
| RGN-137 (Tβ4 dermal gel) |
Epidermolysis Bullosa (EB) Pressure and Venous Stasis Ulcers Scarring and Burns |
12K >3M TBD |
*Company estimates
**Stage 2 & 3, based on EU prevalence data and Clin Ophthalmol. 2014; 8: 571–579.